Verve Therapeutics (VERV) Competitors $11.13 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV vs. BEAM, PTCT, ACLX, MRUS, ZLAB, SRRK, ACAD, VKTX, SWTX, and PTGXShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Beam Therapeutics (BEAM), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Its Competitors Beam Therapeutics PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Protagonist Therapeutics Beam Therapeutics (NASDAQ:BEAM) and Verve Therapeutics (NASDAQ:VERV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Is BEAM or VERV more profitable? Verve Therapeutics has a net margin of -303.64% compared to Beam Therapeutics' net margin of -609.24%. Verve Therapeutics' return on equity of -35.81% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-609.24% -44.24% -30.97% Verve Therapeutics -303.64%-35.81%-27.57% Does the media refer more to BEAM or VERV? In the previous week, Beam Therapeutics had 4 more articles in the media than Verve Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 10 mentions for Verve Therapeutics. Beam Therapeutics' average media sentiment score of 0.66 beat Verve Therapeutics' score of 0.29 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verve Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer BEAM or VERV? Beam Therapeutics presently has a consensus target price of $48.75, indicating a potential upside of 124.45%. Verve Therapeutics has a consensus target price of $14.57, indicating a potential upside of 30.92%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in BEAM or VERV? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 19.9% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, BEAM or VERV? Verve Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M34.39-$376.74M-$4.61-4.71Verve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27 Which has more risk & volatility, BEAM or VERV? Beam Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. SummaryBeam Therapeutics beats Verve Therapeutics on 10 of the 17 factors compared between the two stocks. Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$992.13M$2.49B$5.70B$9.50BDividend YieldN/A1.65%4.58%4.00%P/E Ratio-5.279.1828.3920.08Price / Sales30.69609.56430.0899.95Price / CashN/A165.2136.2258.56Price / Book1.915.168.675.88Net Income-$198.71M$30.99M$3.25B$258.89M7 Day Performance2.02%7.73%4.30%3.70%1 Month Performance-1.15%16.27%10.57%11.71%1 Year Performance50.41%-1.88%35.68%17.98% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics2.9798 of 5 stars$11.13flat$14.57+30.9%+49.8%$992.13M$32.33M-5.27110News CoverageAnalyst UpgradeBEAMBeam Therapeutics2.259 of 5 stars$21.17+0.0%$48.75+130.3%-32.5%$2.13B$63.52M-4.59510Analyst RevisionPTCTPTC Therapeutics4.4387 of 5 stars$49.46+1.9%$65.00+31.4%+33.3%$3.92B$806.78M7.601,410News CoveragePositive NewsAnalyst RevisionACLXArcellx2.286 of 5 stars$69.92+1.4%$111.23+59.1%+13.8%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus1.8941 of 5 stars$55.62+2.1%$84.64+52.2%+23.0%$3.85B$36.13M-13.6337Upcoming EarningsZLABZai Lab3.1271 of 5 stars$34.28+4.7%$54.28+58.3%+97.0%$3.81B$398.99M-13.771,869Positive NewsGap UpSRRKScholar Rock3.43 of 5 stars$38.59+3.1%$42.67+10.6%+312.2%$3.66B$33.19M-15.25140Positive NewsACADACADIA Pharmaceuticals4.1503 of 5 stars$21.89+4.3%$27.88+27.3%+25.3%$3.66B$957.80M15.98510Positive NewsAnalyst ForecastVKTXViking Therapeutics4.8451 of 5 stars$31.63+1.7%$87.15+175.5%-46.8%$3.55BN/A-27.5020Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSWTXSpringWorks Therapeutics1.2655 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230PTGXProtagonist Therapeutics1.3746 of 5 stars$55.23+4.2%$66.10+19.7%+32.7%$3.42B$434.43M73.64120News CoverageInsider Trade Related Companies and Tools Related Companies Beam Therapeutics Competitors PTC Therapeutics Competitors Arcellx Competitors Merus Competitors Zai Lab Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors SpringWorks Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERV) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
